Stay updated on SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.

Latest updates to the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial involving 4SC-202 and Pembrolizumab, while retaining the mention of Malignant Melanoma and the revision number.SummaryDifference19%
- Check17 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check24 days agoNo Change Detected
- Check53 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check74 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check82 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check96 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.